🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mustafa Özgüroğlu

Istanbul University-Cerrahpaşa

ORCID: 0000-0002-8417-8628

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer”.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology(2022)10.1200/jco.21.01308

N/A

7.3DataRank · unranked

1324 citations

Corinne Faivre‐Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz‐Ares +20 more

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.015

N/A

6.9DataRank · unranked

471 citations

David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste +18 more

971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

Annals of Oncology(2022)10.1016/j.annonc.2022.07.1097

N/A

0DataRank · unranked

6 citations

Benjamin Levy, H. Horinouchi, J. Yu, Elizabeth M. Grainger, P. Phuong +4 more

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

UNC Libraries(2022)10.17615/wdx5-cx34

N/A

0DataRank · unranked

2 citations

A.S. Merseburger, D. Cella, S. Chowdhury, E. Basch, B. Miladinovic +16 more